Novartis Investigative Site
Seoul, South Korea
2,181 recruiting
Showing 1–20 of 197 trials
Recruiting
Phase 1
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Advanced Malignancies
Novartis Pharmaceuticals24 enrolled5 locationsNCT07340190
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled60 locationsNCT05948943
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled33 locationsNCT07206056
Recruiting
Phase 1Phase 2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled7 locationsNCT07468071
Recruiting
Phase 1
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled8 locationsNCT07422610
Recruiting
Phase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
Novartis Pharmaceuticals1,400 enrolled229 locationsNCT05827081
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled21 locationsNCT07226986
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Acute Coronary Syndrome
Novartis Pharmaceuticals300 enrolled63 locationsNCT07102628
Recruiting
Phase 3
Study of Out of Specification for Tisagenlecleucel
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled54 locationsNCT04094311
Recruiting
Phase 4
Dabrafenib and/or Trametinib Rollover Study
MelanomaNon-small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals100 enrolled32 locationsNCT03340506
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Sickle Cell Disease
Novartis Pharmaceuticals354 enrolled32 locationsNCT06439082
Recruiting
Phase 1Phase 2
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Acute Lymphoblastic LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Novartis Pharmaceuticals50 enrolled1 locationNCT07387926
Recruiting
Phase 1Phase 2
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Novartis Pharmaceuticals80 enrolled4 locationsNCT07564401
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Asthma
Novartis Pharmaceuticals188 enrolledNCT05776927
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals208 enrolled3 locationsNCT07570979
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 1
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction
Novartis Pharmaceuticals12 enrolled4 locationsNCT07465653
Recruiting
Phase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled30 locationsNCT07357727
Recruiting
Phase 1Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Sickle Cell Disease
Novartis Pharmaceuticals161 enrolled9 locationsNCT06546670
Recruiting
Phase 1
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
Triple-Negative Breast CancerAdvanced Breast CancerAdvanced Non-Small Cell Lung Cancer+1 more
Novartis Pharmaceuticals66 enrolledNCT07801508